First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, David P., Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M. +21 more·2017·New England Journal of Medicine
DOI 10.1056/nejmoa1613493

Cited by (1,001)

Items 1,001–1,001 of 1,001

  1. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
    Zhou, Caicun, Wang, Ziping, Sun, Meili, Cao, Lejie, Ma, Zhiyong, Wu, Rong, Yu, Yan, Yao, Wenxiu, Sun, Si, Chen, Jianhua et al. · 2025 · The Lancet Oncology